Amaç: Düşük doz büyüme hormon tedavisi ile sağlanabilecek maddi kazanç ihtimalini ortaya koymak için bu çalışma planlandı. Olgular ve Metod: Büyüme hormonu eksikliği olan 97 çocuk 2 grupta incelendi. 1)Çalışma grubuna (n=39) rekombinant insan büyüme hormonu (rhGH) 0.15 mg/kg/ hafta dozunda verildi. 2)Kontrol grubuna (n=58), rhGH klasik doz olan 0.2 mg/kg / hafta dozunda verildi. Tüm olgular çalışma başlangıcında ve büyüme hormon tedavisinin 6. ve 12.aylarında değerlendirilip oksolojik kontrolleri yapıldı ve insülin benzeri büyüme faktörü (IGF-1) ile insülin benzeri büyüme faktörü bağlayıcı protein -3 (IGFBP-3) seviyeleri ölçüldü. Bulgular: Kontrol grubu ile karşılaştırıldığında çalışma grubunda: Tedavinin 6.ayında IGF-1, IGFBP3, büyüme hızı (GV) ve büyüme hızı SDS (GVSDS) değerlerinde istatistiksel anlamlı fark bulunamazken, tedavinin 12.ayında kontrol grubunda GV ve GVSDS seviyeleri anlamlı yüksek bulundu. Bu fark kontrol grubunda bu dönemde gözlenen pubertal sıçramaya bağlandı. Her 2 grupta; GV ve GVSDS ile parental boy, hedef boy, IGF-1, IGFBP-3 değerleri arasında istatistiksel anlamlı fark bulunamadı. Sonuç: Büyüme hormonu tedavisinde halen kullanılmakta olan konvansiyonel dozun azaltılması büyüme üzerinde anlamlı olumsuz etki yapmadığından daha düşük doz tedavi ile tedavi maliyetlerinde yaklaşık %20 civarında azalma sağlanabilir ki, bu tüm ülkeler için total tedavi harcamalarını azaltmada çok önemli bir kazanç olabilir.
Objective: The prospect of financial savings by decreasing growth hormone dose, prompted us to study the effectiveness of lower dose treatment. Subjects and methods: We studied 97 growth hormone deficient (GHD) children in two groups: 1) The study group (n=39) was treated with recombinant human GH (rhGH) at a low dose of 0.15 mg/kg/week 2) The control group (n=58) was treated with rhGH, at a conventional dose of 0.2 mg/kg/week. All patients were evaluated for auxology, Insulin like growth factor-1(IGF-1) and Insulin like growth factor binding protein-3(IGFBP3) levels at baseline, 6 and 12 months after starting GH therapy. Results: While there was no significant difference in IGF-1, IGFBP3, growth velocity (GV), and growth velocity SDS (GVSDS) levels after 6 months of therapy between the two groups, the GV and GVSDS levels were significantly higher in the control group after 12 months. This difference contributed to significant pubertal spurt in the control group. In both groups, no significant correlation was found among parental heights, target heights, IGF-1 and IGFBP3 levels with GV and GVSDS. Conclusion: By decreasing the conventional GH treatment dose, we also decrease the cost of GH treatment approximately by 20% which may lead to an important cut in the treatment related cost
Other ID | JA94NG45EM |
---|---|
Journal Section | Research Article |
Authors | |
Publication Date | August 1, 2010 |
Submission Date | August 1, 2010 |
Published in Issue | Year 2010 Volume: 4 Issue: 2 |
The publication language of Turkish Journal of Pediatric Disease is English.
Manuscripts submitted to the Turkish Journal of Pediatric Disease will go through a double-blind peer-review process. Each submission will be reviewed by at least two external, independent peer reviewers who are experts in the field, in order to ensure an unbiased evaluation process. The editorial board will invite an external and independent editor to manage the evaluation processes of manuscripts submitted by editors or by the editorial board members of the journal. The Editor in Chief is the final authority in the decision-making process for all submissions. Articles accepted for publication in the Turkish Journal of Pediatrics are put in the order of publication taking into account the acceptance dates. If the articles sent to the reviewers for evaluation are assessed as a senior for publication by the reviewers, the section editor and the editor considering all aspects (originality, high scientific quality and citation potential), it receives publication priority in addition to the articles assigned for the next issue.
The aim of the Turkish Journal of Pediatrics is to publish high-quality original research articles that will contribute to the international literature in the field of general pediatric health and diseases and its sub-branches. It also publishes editorial opinions, letters to the editor, reviews, case reports, book reviews, comments on previously published articles, meeting and conference proceedings, announcements, and biography. In addition to the field of child health and diseases, the journal also includes articles prepared in fields such as surgery, dentistry, public health, nutrition and dietetics, social services, human genetics, basic sciences, psychology, psychiatry, educational sciences, sociology and nursing, provided that they are related to this field. can be published.